Roche Holding ROP -0.31%decrease; down pointing triangle said it stopped work on one of its obesity-drug candidates, after clinical-trial data suggested the medicine wouldn’t hit internal targets.
The Swiss drugmaker said it returned rights to the medicine, emugrobart, to its majority-owned business Chugai Pharmaceutical 4519 2.74%increase; up pointing triangle, which originally discovered the drug and licensed it to Roche.
Copyright ©2026 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8